MDxHealth SA (MDXH): Price and Financial Metrics
GET POWR RATINGS... FREE!
MDXH Stock Price Chart Interactive Chart >
MDXH Price/Volume Stats
|Current price||$6.91||52-week high||$10.95|
|Prev. close||$6.94||52-week low||$6.00|
|Day high||$6.91||Avg. volume||18,080|
|50-day MA||$7.09||Dividend yield||N/A|
|200-day MA||$7.68||Market Cap||112.55M|
MDxHealth SA (MDXH) Company Bio
MDxHealth SA operates as a molecular diagnostics company in Belgium, the Netherlands, Spain, Poland, Italy, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on proprietary genetic, epigenetic, and other molecular technologies, as well as assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's product pipeline includes tests for bladder, kidney, and other urologic cancers. Its products include ConfirmMDx, a tissue test for prostate cancer; and SelectMDx, a non-invasive urine test for prostate cancer. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Most Popular Stories View All
MDXH Latest News Stream
|Loading, please wait...|
MDXH Latest Social Stream
View Full MDXH Social Stream
Latest MDXH News From Around the Web
Below are the latest news stories about MDXHEALTH SA that investors may wish to consider to help them evaluate MDXH as an investment opportunity.
NEWS RELEASE – INSIDE AND REGULATED INFORMATION29 NOVEMBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Provides Business Update IRVINE, CA, and HERSTAL, BELGIUM – November 29, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today provided clinical and reimbursement product developments, updated guidance for 2022, and initial guidance for 2023. Select mdx reimbursement update Under the foundational LCD (Local Coverage Decision) process recently implemente
Madison-based cancer screening and diagnostic test maker Exact Sciences Corp. said Thursday it expects to turn profitable in the third quarter of 2023, ahead of its previous target of 2024.
NEWS RELEASE - REGULATED INFORMATION27 OCTOBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Reports Q3-2022 Results IRVINE, CA, and HERSTAL, BELGIUM – October 27, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today announced its financial results for the third quarter ended September 30, 2022. Michael K. McGarrity, CEO of mdxhealth, commented: “We are pleased to report continued strong operating results for the third quarter 2022. Our focus on operating
NEWS RELEASE - REGULATED INFORMATION25 AUGUST 2022, 4:00PM EDT, 22:00 CET MDxHealth Reports Half Year 2022 Results IRVINE, CA, and HERSTAL, BELGIUM – August 25, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today announced its financial results for the half year ended June 30, 2022. Michael K. McGarrity, CEO of mdxhealth, commented: “We are excited to report strong operating results for the first half of 2022, couple
NEWS RELEASE - REGULATED INFORMATIONAugust 19, 2022, 4:00 PM EDT / 22:00 CET Mdxhealth's New Share Capital Amount and New Number of Shares IRVINE, CA, and HERSTAL, BELGIUM – August 19, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today a announces, in accordance with Article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulate
MDXH Price Returns